Adagene Announces that Third Arc Bio Has Selected First Lead Candidate under Amended Strategic Collaboration for Development of Masked CD3 T Cell Engagers Utilizing SAFEbody® Technology
Go back to Adagene Announces that Third Arc Bio Has Selected First Lead Candidate under Amended Strategic Collaboration for Development of Masked CD3 T Cell Engagers Utilizing SAFEbody® Technology| (NASDAQ: ADAG) | Delayed: 3.31 +0.04 (1.22%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $3.27 | 52 Week High | $ | |||
| Open | $3.54 | 52 Week Low | $ | |||
| Day High | $3.55 | P/E | N/A | |||
| Day Low | $3.20 | EPS | $ | |||
| Volume | 224,590 | |||||
